Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Avacta Group (AVCT) Share Price

Price 77.00p on 17-04-2026 at 18:50:06
Change 2.00p 2.67%
Buy 78.00p
Sell 76.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 60,913.00 at 77.00p
Day's Volume: 3,224,068
Last Close: 77.00p
Open: 74.60p
ISIN: GB00BYYW9G87
Day's Range 74.60p - 77.00p
52wk Range: 27.25p - 83.20p
Market Capitalisation: £349.20m
VWAP: 76.56427p
Shares in Issue: 453.51m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Avacta Group (AVCT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 60,913 77.00p OTC Trade
 17:06:41 - 17-Apr-26
Sell* 250,000 76.25p Ordinary
 16:37:11 - 17-Apr-26
Sell* 100,000 75.89p Negotiated Trade
 16:37:03 - 17-Apr-26
Buy* 1 77.3744p Ordinary
 16:23:51 - 17-Apr-26
Sell* 72,179 76.20p Ordinary
 16:23:41 - 17-Apr-26
Buy* 37,192 77.3899p Ordinary
 16:22:44 - 17-Apr-26
Buy* 1,283 77.40p Ordinary
 16:21:05 - 17-Apr-26
Buy* 15,000 77.45p Ordinary
 16:20:36 - 17-Apr-26
Buy* 300 77.50p Ordinary
 16:19:01 - 17-Apr-26
Buy* 5,161 77.50p Ordinary
 16:18:59 - 17-Apr-26
See more Avacta Group trades

Avacta Group (AVCT) Share Price History

Time period:
to
Date Open High Low Close Volume
17th Apr 2026 (Fri) 74.60 77.00 74.60 77.00 3,224,068
16th Apr 2026 (Thu) 74.50 77.50 74.50 75.00 2,000,664
15th Apr 2026 (Wed) 72.00 76.50 74.00 74.00 3,098,313
14th Apr 2026 (Tue) 69.00 72.50 70.00 72.00 1,917,779
13th Apr 2026 (Mon) 70.00 70.00 68.00 68.00 1,280,226
10th Apr 2026 (Fri) 70.00 70.50 69.50 70.00 2,527,374
9th Apr 2026 (Thu) 70.00 71.00 69.80 71.00 2,567,623
8th Apr 2026 (Wed) 68.50 70.00 68.20 68.20 3,110,735
7th Apr 2026 (Tue) 64.00 66.20 65.50 66.20 5,131,954
6th Apr 2026 (Mon) 63.50 63.50 63.50 63.50 0
3rd Apr 2026 (Fri) 63.50 63.50 63.50 63.50 0
2nd Apr 2026 (Thu) 63.00 63.50 63.00 63.50 1,704,320
1st Apr 2026 (Wed) 63.50 65.00 63.50 64.00 1,757,236
31st Mar 2026 (Tue) 64.50 65.00 63.50 63.50 2,288,945
30th Mar 2026 (Mon) 63.60 65.00 63.60 64.50 2,470,778
27th Mar 2026 (Fri) 64.00 65.20 65.20 65.20 9,040,828
26th Mar 2026 (Thu) 69.50 70.00 68.00 68.50 903,922
25th Mar 2026 (Wed) 67.50 70.50 67.50 69.50 1,421,971
24th Mar 2026 (Tue) 66.50 68.00 66.50 67.50 1,166,004
23rd Mar 2026 (Mon) 68.00 68.00 65.00 66.50 1,599,328
20th Mar 2026 (Fri) 66.00 69.00 69.00 69.00 856,931
19th Mar 2026 (Thu) 69.00 67.00 65.00 66.00 1,162,168
See more Avacta Group price history

Avacta Group (AVCT) Regulatory News

Date Source Headline
14th Apr 2026 11:37 am RNS-R Christina Coughlin - In Vivo 2026 Rising Leader
9th Apr 2026 7:00 am RNS Q1 2026 Business Update
8th Apr 2026 7:00 am RNS-R Avacta Announces Science Day 2026
31st Mar 2026 7:00 am RNS First patient treated in Phase 1 trial of AVA6103
27th Mar 2026 7:00 am RNS Result of Oversubscribed Fundraise
26th Mar 2026 5:16 pm RNS Proposed Fundraise to raise approximately £10m
26th Mar 2026 4:44 pm RNS Issue of Equity
17th Mar 2026 7:00 am RNS-R Presentations of pre|CISION® Platform Candidates
17th Mar 2026 7:00 am RNS-R Presentations of pre|CISION® Platform Candidates
16th Mar 2026 7:00 am RNS Phase 1 study opening for AVA6103
See more Avacta Group regulatory news

Avacta Group (AVCT) Share News

TRADING UPDATES: Somero Enterprises extends buyback to USD6.0 million

9th Apr 2026 20:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Avacta hails "important milestones" in start of "transformative" year

9th Apr 2026 13:04

(Alliance News) - Avacta Group PLC on Thursday said it "continued to build momentum" in the first quarter, highlighting favourable developments for its oncology products. Read More

IN BRIEF: Avacta raises GBP10 million in equity for clinical tests

27th Mar 2026 09:22

Avacta Group PLC - London-based biopharmaceutical company developing a tumour-activated oncology delivery platform - Raises GBP10 million from a placing of and subscription to 15.9 million new shares at 63 pence each. The new shares represent 3.6% of Avacta's total prior to the issuance. Two non-executive directors, Richard Hughes and David Bryant, contribute a total of GBP550,000 to the raise. The share offer is run by Zeus Capital as broker and bookrunner. Zeus will receive warrants over 4.4 million new shares at the same 63p price, exercisable over five years. The raise is in line with the plan announced after the London market close on Thursday. The fresh cash will be used to progress Avacta's research and development programmes into early in the first quarter of 2027, providing enough cash to get to initial data from a phase 1a trial of AVA6103, its second clinical program. AVA6103, a peptide drug conjugate. Read More

Avacta opens phase 1 trial for conjugate's efficacy regarding tumours

16th Mar 2026 12:00

(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More

Avacta hails new data supporting proprietary preCision platform

24th Feb 2026 11:06

(Alliance News) - Avacta Group PLC on Tuesday saw its shares rise, as it said new data demonstrates a favourable delivery profile and advantages of its preCision platform when compared to a marketed antibody drug conjugate. Read More

See more Avacta Group news
FTSE 100 Latest
Value10,667.63
Change77.64

Login to your account

Forgot Password?

Not Registered